Therapeutic Asset Ratings

13,145 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Pentoxifylline 46 XX Gonadal Dysgenesis	Ain Shams University	P2	B (57)
Pentoxifylline Chemotherapy-Induced Neuropathy	Mansoura University	P2	B (57)
Pertuzumab Urinary Bladder Carcinoma	National Cancer Institute (NCI)	P2	B (57)
Pertuzumab Colorectal Cancer	Fudan University	P2	B (57)
[Phe^2,Ile^3,Dab(Phac-D-Tyr(Me)-Phe-Gln-Asn-Ala-Pro-Arg-Igln-Lys(Ac)-Epsilon-Lys)^8]Vasopressin Acute Kidney Injury	Ocelot Bio, Inc	P2	B (57)
[Phe^2,Ile^3,Dab(Phac-D-Tyr(Me)-Phe-Gln-Asn-Ala-Pro-Arg-Igln-Lys(Ac)-Epsilon-Lys)^8]Vasopressin Cirrhosis Of Liver	Ocelot Bio, Inc	P2	B (57)
[Phe^2,Ile^3,Dab(Phac-D-Tyr(Me)-Phe-Gln-Asn-Ala-Pro-Arg-Igln-Lys(Ac)-Epsilon-Lys)^8]Vasopressin Hepatorenal Syndrome	Ocelot Bio, Inc	P2	B (57)
Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]- Childhood Malignant Neoplasm	Sun Yat-sen University	P2	B (57)
PI3K/MTOR INHIBITOR LY3023414 Non-Hodgkin Lymphoma	National Cancer Institute (NCI)	P2	B (57)
PI3K/MTOR INHIBITOR LY3023414 Langerhans Cell Histiocytosis	National Cancer Institute (NCI)	P2	B (57)
PI3K/MTOR INHIBITOR LY3023414 Rhabdomyosarcoma	National Cancer Institute (NCI)	P2	B (57)
PI3K/MTOR INHIBITOR LY3023414 Ependymoma	National Cancer Institute (NCI)	P2	B (57)
PI3K/MTOR INHIBITOR LY3023414 Glioma	National Cancer Institute (NCI)	P2	B (57)
PI3K/MTOR INHIBITOR LY3023414 Neuroblastoma	National Cancer Institute (NCI)	P2	B (57)
PI3K/MTOR INHIBITOR LY3023414 Peripheral Primitive Neuroectodermal Tumor	National Cancer Institute (NCI)	P2	B (57)
Pipe-307 Relapsing-Remitting Multiple Sclerosis	Contineum Therapeutics	P2	B (57)
Polatuzumab Vedotin Indolent B-Cell Non-Hodgkin Lymphoma	University of Washington	P2	B (57)
Polatuzumab Vedotin B-Cell Non-Hodgkin Lymphoma	Brown University	P2	B (57)
Ponatinib Chronic Myeloid Leukemia	Otsuka Beijing Research Institute	P2	B (57)
Ponatinib Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	M.D. Anderson Cancer Center	P2	B (57)
Prednisone Cognitive Disorder	Beijing Friendship Hospital	P2	B (57)
Prednisone Disease Of Genetic Or Genomic Mechanism	Instituto do Cancer do Estado de São Paulo	P2	B (57)
Prednisone Precursor Lymphoblastic Lymphoma/Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	B (57)
Prolgolimab Colorectal Cancer	Blokhin's Russian Cancer Research Center	P2	B (57)
Proliverenol Metabolic Dysfunction-Associated Steatotic Liver Disease	Dexa Medica Group	P2	B (57)

Showing 3376 to 3400 of 13,145 assets

PreviousPage 136 of 526Next